Mirum Pharmaceuticals, Inc. - common stock (MIRM)

Mirum Pharmaceuticals (NASDAQ:MIRM) reported second-quarter net product sales of $176 million and raised its full-year 2026 product sales outlook to $680 million to $700 million, while outlining several upcoming clinical and regulatory milestones across its rare liver and rare genetic disease portfo

Mirum Pharmaceuticals (NASDAQ:MIRM) executives said the rare disease company is entering a catalyst-heavy period, with recent positive clinical updates, ongoing commercial momentum for LIVMARLI and additional business development activity expanding its portfolio. Speaking at RBC Capital Markets’ 20

Mirum stock pulled back after earnings despite strong growth. Here’s why investors still see upside in the rare disease biotech company

This online marketplace connects U.S. consumers with consigned luxury goods, spanning apparel, jewelry, art, and home products.

Mirum (MIRM) Q1 2026 Earnings Call Transcript

Vertex Pharmaceuticals has given Mirum Pharmaceuticals the blueprint for success in rare diseases.

This small biotech could grow much larger with some good news from its pipeline.

Mirum (MIRM) Q2 2025 Earnings Call Transcript

Mirum Pharma (MIRM) Earnings Call Transcript

Mirum (MIRM) Q1 2025 Earnings Call Transcript

This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and systemic mastocytosis.

This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms.

HealthEquity delivers cloud-based healthcare savings solutions to employers and individuals, with a broad client network across the U.S.

NEW YORK — The euphoric "small-cap comeback" that defined the opening weeks of 2026 came to a grinding halt on Thursday. The Russell 2000 index, the primary barometer for American small-cap health, plummeted 1.9% on March 5, 2026, marking its sharpest single-day decline of the year. The sell-off, triggered by

Mirum (MIRM) Q4 2025 Earnings Call Transcript

Penn Capital initiated a position in ACM Research, which supplies cleaning and plating tools used in advanced semiconductor manufacturing. As AI-driven chip designs grow more complex, precision equipment becomes more valuable, but demand remains tied to export controls and capital spending cycles.

Arcellx develops cell-based immunotherapies targeting cancer, with a lead candidate in early-stage trials for multiple myeloma.

Cogent Biosciences develops precision therapies for genetically defined diseases, with a pipeline targeting rare oncological conditions.

This clinical-stage biotech develops therapies for NASH and obesity, advancing a diverse pipeline of small-molecule drug candidates.